Product name:Cediranib
CAS: 288383-20-0
Molecular Formula: C25H27FN4O3
Molecular Weight: 450.51
Product description:An oral antineoplastic drugs, developed by American astrazeneca company, brand name recentin, this product is a highly VEGFR tyrosine kinase inhibitor, can inhibit all known VEGFR tyrosine kinase (including, VEGFR - 2, VEGFR VEGFR - 1-3 and PDGFR). West to Nebuchadnezzar can inhibit the angiogenesis induced by VEGF and angiogenesis survival and growth of human xenograft tumor cells. For non-small cell lung cancer (NSCLC) in patients with stage I study found that sildenafil Nebuchadnezzar with PC scheme combined use of anti-tumor effect is remarkable. Ⅱ/Ⅲ study BR24 for west to Nebuchadnezzar 30 mg as first-line treatment in patients with NSCLC scheme was studied, and prove its have antitumor effect, but with a greater incidence of adverse events, including diarrhea, dehydration, the brotherhood of syndrome, high blood pressure, and neutropenia.